Why the Pharmaceutical Industry Needs Implementation Science for Sustainable Innovation.
- Published in:
- Pharmaceutical Medicine, 2025, v. 39, n. 3, p. 147, doi. 10.1007/s40290-025-00566-x
- By:
- Publication type:
- Article
Works matching DE "PHARMACEUTICAL industry
Results: 5000
1
2
Cost and Duration of Clinical Trials in Drug Development by Japanese Pharmaceutical Companies.
- Published in:
- Pharmaceutical Medicine, 2025, v. 39, n. 3, p. 199, doi. 10.1007/s40290-025-00558-x
- By:
- Publication type:
- Article
3
Artificial Intelligence: Applications in Pharmacovigilance Signal Management.
- Published in:
- Pharmaceutical Medicine, 2025, v. 39, n. 3, p. 183, doi. 10.1007/s40290-025-00561-2
- By:
- Publication type:
- Article
4
Editorial Board.
- Published in:
- 2014
- Publication type:
- Index
5
Editorial Collaborators.
- Published in:
- 2013
- Publication type:
- Editorial
6
Accelerating access to medical products in the Eastern Mediterranean Region.
- Published in:
- 2025
- By:
- Publication type:
- Editorial
7
Efficient micropropagation, genetic validation and phytochemical profiling of Rumex hastatus D. Don- an edible medicinal herb of Western Himalayas.
- Published in:
- In Vitro Cellular & Developmental Biology Plant, 2025, v. 61, n. 2, p. 369, doi. 10.1007/s11627-025-10526-4
- By:
- Publication type:
- Article
8
Modern biomedicine in global economy and Ukraine.
- Published in:
- Socrates Almanac, 2017, p. 11
- By:
- Publication type:
- Article
9
Synthesis of α‐Aryl and α‐Heteroaryl 4‐Silyloxy Piperidines via a One‐Pot Negishi Cross‐Coupling Approach.
- Published in:
- Chemistry - A European Journal, 2025, v. 31, n. 31, p. 1, doi. 10.1002/chem.202500863
- By:
- Publication type:
- Article
10
IN-VITRO COMPARATIVE EVALUATION OF BRANDED AND GENERIC FUROSEMIDE40MG TABLET.
- Published in:
- Advances in Pharmacology & Toxicology, 2024, v. 24, n. 2, p. 69
- By:
- Publication type:
- Article
11
NKure and CRISPR Partners to Develop Of-the-Shelf CAR T Therapy in India.
- Published in:
- Indian Practitioner, 2025, v. 78, n. 5, p. 41
- Publication type:
- Article
12
J&J MedTech, Qure.ai Partner for Early Lung Cancer Detection.
- Published in:
- Indian Practitioner, 2025, v. 78, n. 5, p. 40
- Publication type:
- Article
13
EMA approved orphan medicines since the implementation of the orphan legislation.
- Published in:
- Orphanet Journal of Rare Diseases, 2025, v. 20, n. 1, p. 1, doi. 10.1186/s13023-025-03756-7
- By:
- Publication type:
- Article
14
It's Time to Break Up: Dynamics Surrounding Young-Established Firm Alliance Duration.
- Published in:
- Production & Operations Management, 2025, v. 34, n. 6, p. 1276, doi. 10.1177/10591478241279551
- By:
- Publication type:
- Article
15
Advances in the biosynthesis of tetraacetyl phytosphingosine, a key substrate of ceramides.
- Published in:
- Synthetic & Systems Biotechnology, 2025, v. 10, n. 1, p. 1, doi. 10.1016/j.synbio.2024.07.005
- By:
- Publication type:
- Article
16
Determination of Chlorpheniramine Maleate in its Pharmaceutical Preparations Using Homemade Turbidity Flow Injection Analyzer.
- Published in:
- Baghdad Science Journal, 2025, v. 22, n. 5, p. 1451, doi. 10.21123/bsj.2024.10244
- By:
- Publication type:
- Article
17
Chemical Composition of the Leaf Essential Oil of Tritaxis glabella and Its Free-Radical Scavenging Activity.
- Published in:
- Chemistry of Natural Compounds, 2025, v. 61, n. 3, p. 603, doi. 10.1007/s10600-025-04716-0
- By:
- Publication type:
- Article
18
Green Supply Chain Integration and Sustainable Performance in Pharmaceutical Industry of China: A Moderated Mediation Model.
- Published in:
- Systems, 2025, v. 13, n. 5, p. 388, doi. 10.3390/systems13050388
- By:
- Publication type:
- Article
19
Deciphering the Risk–Return Dynamics of Pharmaceutical Companies Using the GARCH-M Model.
- Published in:
- Risks, 2025, v. 13, n. 5, p. 87, doi. 10.3390/risks13050087
- By:
- Publication type:
- Article
20
Marine-Derived Compounds Combined with Nanoparticles: A Focus on the Biomedical and Pharmaceutical Sector.
- Published in:
- Marine Drugs, 2025, v. 23, n. 5, p. 207, doi. 10.3390/md23050207
- By:
- Publication type:
- Article
21
LETTERS.
- Published in:
- Pulse International, 2025, v. 26, n. 10, p. N.PAG
- By:
- Publication type:
- Article
22
Need for life cycle assessment of pharmaceuticals for kidney healthcare.
- Published in:
- Clinical & Experimental Nephrology, 2025, v. 29, n. 6, p. 702, doi. 10.1007/s10157-025-02647-2
- By:
- Publication type:
- Article
23
Development and Validation of a Sensitive LC-MS/MS Method for the Determination of N-Nitroso-Atenolol in Atenolol-Based Pharmaceuticals.
- Published in:
- Separations (2297-8739), 2025, v. 12, n. 5, p. 122, doi. 10.3390/separations12050122
- By:
- Publication type:
- Article
24
IW-Studie: „Hemmschuh für Pharmastandort Deutschland".
- Published in:
- Pharma + Food, 2025, n. 2, p. 10
- Publication type:
- Article
25
Interview mit Dr. Olaf Weinmann zum Cyber Resilience Act.
- Published in:
- Pharma + Food, 2025, n. 2, p. 24
- Publication type:
- Article
26
CEOs von Novartis und Sanofi : „Wir hoffen, dass Europa die Gunst der Stunde nutzt.".
- Published in:
- Pharma + Food, 2025, n. 2, p. 8
- Publication type:
- Article
27
Heimische Märkte wieder mehr im Fokus.
- Published in:
- Pharma + Food, 2025, n. 2, p. 6
- Publication type:
- Article
28
Top 5 Beiträge.
- Published in:
- Pharma + Food, 2025, n. 2, p. 8
- Publication type:
- Article
29
Körber verbindet globale Standards mit lokaler ExpertiseNahtlose Sekundärverpackungs-Lösungen weltweit.
- Published in:
- Pharma + Food, 2025, n. 2, p. 22
- Publication type:
- Article
30
Rezeptursoftware macht Pharmaproduktion sicherer und effizienter.
- Published in:
- Pharma + Food, 2025, n. 2, p. 60
- Publication type:
- Article
31
Effizient statt überlastet.
- Published in:
- Pharma + Food, 2025, n. 2, p. 64
- Publication type:
- Article
32
Optimising Cancer Medicine in Clinical Practices: Are Neoadjuvant and Adjuvant Immunotherapies Affordable for Cancer Patients in Low- and Middle-Income Countries?
- Published in:
- Cancers, 2025, v. 17, n. 10, p. 1722, doi. 10.3390/cancers17101722
- By:
- Publication type:
- Article
33
Responsibility of the pharmaceutical industry: Sustainability and communication with publics.
- Published in:
- Catalan Journal of Communication & Cultural Studies, 2025, v. 17, n. 1, p. 61, doi. 10.1386/cjcs_00104_1
- By:
- Publication type:
- Article
34
The advisory body on animal ethics of a global pharmaceutical company: A global organization to address ethical and societal concerns about animal use.
- Published in:
- Laboratory Animals, 2025, v. 59, n. 3, p. 390, doi. 10.1177/00236772241302537
- By:
- Publication type:
- Article
35
PRODUCTS & SERVICES.
- Published in:
- 2025
- Publication type:
- Product Review
36
Unlocking access: a comprehensive analysis of medicines accessibility for rare diseases in Thailand.
- Published in:
- Orphanet Journal of Rare Diseases, 2025, v. 20, n. 1, p. 1, doi. 10.1186/s13023-025-03754-9
- By:
- Publication type:
- Article
37
A facile, scalable, and sustainable approach to the preparation of the indole-core of alectinib.
- Published in:
- Bulletin of the Chemical Society of Japan, 2025, v. 98, n. 3, p. 1, doi. 10.1093/bulcsj/uoaf019
- By:
- Publication type:
- Article
38
ANÁLISE DO IMPACTO DA IMPLEMENTAÇÃO DO LEAN SIX SIGMA NA INDÚSTRIA FARMACÊUTICA: UM ESTUDO DE REVISÃO SISTEMÁTICA.
- Published in:
- Revista Fatec Zona Sul (REFAS), 2025, v. 11, n. 4, p. 1, doi. 10.26853/Refas_ISSN-2359-182X_v11n04_05
- By:
- Publication type:
- Article
39
Notizen aus der Wirtschaft.
- Published in:
- Nachrichten aus der Chemie, 2025, v. 73, n. 6, p. 24, doi. 10.1002/nadc.20254151548
- By:
- Publication type:
- Article
40
Announcements.
- Published in:
- Oncology (08909091), 2009, v. 23, n. 7, p. 571
- Publication type:
- Article
41
Announcements.
- Published in:
- Oncology (08909091), 2008, v. 22, n. 14, p. 1634
- Publication type:
- Article
42
Small Steps Forward in the Land of Small Tumors.
- Published in:
- Oncology (08909091), 2008, v. 22, n. 14, p. 1623
- By:
- Publication type:
- Article
43
New Formulation of BLP25 Liposome Vaccine: Phase II Study Interim Results.
- Published in:
- Oncology (08909091), 2005, v. 19, n. 13, p. 1682
- Publication type:
- Article
44
Announcements.
- Published in:
- Oncology (08909091), 2005, v. 19, n. 9, p. 1117
- Publication type:
- Article
45
What's in the Pipeline?
- Published in:
- RT: The Journal for Respiratory Care Practitioners, 2011, v. 24, n. 7, p. 29
- Publication type:
- Article
46
Conflict-Free?
- Published in:
- 2009
- By:
- Publication type:
- Editorial
47
Dividend policy issues in the European pharmaceutical industry: new empirical evidence.
- Published in:
- European Journal of Health Economics, 2023, v. 24, n. 5, p. 803, doi. 10.1007/s10198-022-01510-5
- By:
- Publication type:
- Article
48
How Managed Entry Agreements can improve allocation in the public health system: a mechanism design approach.
- Published in:
- European Journal of Health Economics, 2021, v. 22, n. 5, p. 699, doi. 10.1007/s10198-021-01284-2
- By:
- Publication type:
- Article
49
Efficiency ratio and rocketing drug prices: old concerns and new possibilities.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
50
International impact of external reference pricing: should national policy-makers care?
- Published in:
- 2019
- By:
- Publication type:
- journal article